Company: CERO
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001213900-25-112619
Chunk: 188

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-19
Form: 10-Q
Item: Item 8
Chunk 188
---
 (as defined below), each
holder may alternatively elect to convert the Series D Preferred Stock at the “Series D Alternate Conversion Price”
equal to the lesser of:

    ●
    The applicable Conversion Price, and

    ●
    the greater of:

    ● the floor price of $3.12; and 

    ● 80% of the lowest volume weighted average price of the Common Stock during the five consecutive trading days immediately prior to such conversion. 

The Series D Certificate
of Designations contains standard and customary triggering events (each, a “Series D Triggering Event”), including but
not limited to: (i) the suspension from trading or the failure to list the Common Stock within certain time periods; (ii) failure
to declare or pay any dividend when due; (iii) the failure to timely file or make effective a registration statement on Form S-1
or Form S-3 pursuant to the Registration Rights Agreement (as defined below), (iv) the Company’s failure to cure a conversion
failure or notice of the Company’s intention not to comply with a request for conversion of any Series D Preferred Stock, and
(iv) bankruptcy or insolvency of the Company.

Other Adjustments.
In connection with the April 2025 Private Placement, the Company has agreed to seek stockholder approval at a special meeting of
stockholders, of the issuance of Conversion Shares at a conversion price below the Conversion Price (the date of such approval, the “Series D
Stockholder Approval Date”). If the Company did not obtain such stockholder approval prior to May 31, 2025, then the Company
would have been required to (i) file a preliminary Proxy Statement seeking such stockholder consent with the SEC no later than May 31,
2025, (ii) use reasonable best efforts to file the definitive Proxy Statement no later than June 30, 2025 and (iii) use
reasonable best efforts to hold the Stockholder Meeting no later than July 31, 2025. Such stockholder approval was obtained on May
29, 2025. If, on or after the Series D Stockholder Approval Date, the Company issues any shares of Common Stock for a consideration
per share (the “Series D New Issuance Price”) less than a price equal to the Series D Conversion Price in effect
immediately prior to such issuance, the Conversion Price